have coordinated more than 300 patients from all over the state who have participated in the study<\/strong>, out of a total of more than 6,200 worldwide.<\/p>\nThe results presented at the Barcelona congress and published at the same time in the NEJM show that the administration of dapagliflozin in a single daily oral dose can reduce the compound effect of cardiovascular death and worsening of HF by 18%. In addition, the joint analysis of the DELIVER study and another that has also focused on the drug (DAPA-HF) showed a reduction in the risk of cardiovascular death by 14%<\/strong>.<\/p>\n <\/p>\n
What is dapagliflozin?<\/h3>\n
It is the first inhibitor and sodium-glucose cotransporter 2 or SGLT2 for oral use. Until now, it was approved for type 2 diabetes mellitus treatment<\/strong> as a complement to diet and exercise, because it reduces blood sugar by making the kidneys excrete more glucose in the urine. Marketed by Astra Zeneca, which has promoted the DELIVER trial, dapagliflozin is also approved for the treatment of HF with reduced ejection fraction (LVEF) and chronic kidney disease. As Dr. Comin<\/strong> points out, “now the range of heart failure patients who can count on effective treatment is extended, now includes those with intermediate or slightly reduced LVEF.<\/em>”<\/p>\nHe adds that “The results of the study will represent a change in the current recommendations of international clinical practice guidelines and are a paradigmatic example of knowledge transfer to clinical practice<\/strong> in which the HUB and IDIBELL have contributed significantly<\/em>.”<\/p>\nHeart failure is a chronic disease that worsens over time and that in Spain affects 2% of the population and about 64 million people worldwide. It is the main cause of hospitalization for people over 65 years old and represents a significant health cost.<\/p>\n
<\/p>\n
<\/p>\n
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.<\/em><\/p>\nIDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Dapagliflozin significantly reduces the risk of cardiovascular death and hospitalizations for heart failure (HF).<\/p>\n","protected":false},"author":8,"featured_media":21224,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[206,258,300],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-13 13:40:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/21222"}],"collection":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/comments?post=21222"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/21222\/revisions"}],"predecessor-version":[{"id":21223,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/posts\/21222\/revisions\/21223"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media\/21224"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/media?parent=21222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/categories?post=21222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/en\/wp-json\/wp\/v2\/tags?post=21222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}